Global /Norway /Healthcare /Medical Devices /GENT
chevron_leftBack
Gentian Diagnostics ASA logo

Gentian Diagnostics ASA

GENT
OSL: GENT Delayed
40.60NOK -6.7%
4.29 USD
As of 6 June 2026, Gentian Diagnostics ASA has a market cap of $71.96M USD, ranking #27925 globally and #173 in Norway. It ranks #2520 in the Healthcare sector, and #514 in the Medical Devices industry.
Global Rank
27925
Country Rank
173
Sector Rank
2520
Industry Rank
514
Key Stats
Market Cap
$71.96MUSD
672.45M NOK
Enterprise Value
$62.28MUSD
589.51M NOK
Revenue (TTM)
$18.89MUSD
176.5M NOK
EBITDA (TTM)
$3.01MUSD
28.52M NOK
Net Income (TTM)
$1.42MUSD
13.26M NOK
EBITDA Margin
16%
Profit Margin
7.5%
PE Ratio
50.6
Forward PE
16.6
PS Ratio
3.8
PB Ratio
3.3
EV/EBITDA
18.2
Company Profile
Country (HQ)
Sector
Healthcare
Industry
Medical Devices
CEO
Matti Heinonen open_in_new
Employees
64
Founded
2001
Website
gentian.com open_in_new
warningChart data may be delayed
1d 1w 1m 3m 6m 1y
-6.7% -2.9% 14% -25% -21% -12%

News

Loading...

Markets

Exchange Ticker Price
Euronext Oslo Børs
MIC: XOSL
PRIMARY
GENT
Gentian Diagnostics AS
ISIN: NO0010748866
Shares Out.:
15.459M1 Shares Float: 7.798M2
TV:
SA:
YF:
GF:
BA:
MS:
40.60 NOK
Nasdaq Stockholm
MIC: XSTO
GENTOo (GENTO)
Gentian Diagnostics AS
ISIN: NO0010748866
TV:
SA:
YF:
GF:
BA:
MS:
37.20 NOK
Frankfurt Stock Exchange
MIC: XFRA
6FK
Gentian Diagnostics AS
ISIN: NO0010748866
TV:
SA:
YF:
GF:
BA:
6FK
MS:
3.92 EUR
1Market cap is calculated using shares outstanding.
2Float shares are publicly tradable shares, excluding insider-held stock.

About Gentian Diagnostics ASA

Gentian Diagnostics ASA develops, manufactures, and sells biochemical reagents for use in medical diagnostics and research in the United States, Asia, and Europe. It offers in-vitro diagnostic reagents for clinical chemistry analyzers, such as Gentian Calprotectin Immunoassay, a turbidimetric assay used for the measurement of circulating calprotectin in plasma and serum for detection and assessment of inflammation; Gentian Cystatin C Immunoassay test kit, a GFR marker for the diagnosis and therapeutic control of renal function and chronic kidney disease; Gentian Retinol-Binding Protein Immunoassay for detection of retinol-binding protein in human serum and plasma; and Canine CRP Immunoassay test kit, a particle-enhanced turbidimetric immunoassay for quantitative determination of canine C-reactive protein in dog plasma and serum. The company also develops faecal calprotectin immunoassay turbo that offers results of calprotectin concentration in stool supporting diagnosis of inflammatory bowel disease; and faecal pancreatic elastase immunoassay turbo, which allows analysis of pancreatic elastase in stool to aid in diagnosis of pancreatic exocrine insufficiency. Gentian Diagnostics ASA was founded in 2001 and is headquartered in Moss, Norway.

Similar Companies

Industry: Medical Devices (Norway)
Name
Market Cap diff.
PE
MEDI
$450.22M
4.21B NOK
526%
26.4
PHO
$191.61M
1.79B NOK
166%
-
$113.67M
1.06B NOK
58%
109.5
$40.83M
381.57M NOK
-43%
-
LIFE
$12.76M
119.25M NOK
-82%
-
Industry: Medical Devices (Global)
Name
Market Cap diff.
PE
$173.27B
241K%
25.8
$160.73B
223K%
56.7
$159.07B
221K%
25.6
DHR
$126.55B
176K%
34.7
SYK
$120.69B
168K%
38.3
MDT
$101.9B
142K%
22.2
chevron_leftBack